Mangoceuticals' MGX-0024 Shows Strong Antiviral Efficacy in Poultry Trials, H5N1 Study
MGRX sits 43% above its 52-week low of $0.34.
Summary
Mangoceuticals announced positive data for its antiviral compound MGX-0024, demonstrating zero respiratory-related mortality in large poultry field trials and prophylactic benefits against H5N1 in a controlled study.
Key Events · Product Development and Regulatory · MGRX
-
Antiviral Compound Shows Strong Efficacy
Mangoceuticals announced new data for its proprietary antiviral compound MGX-0024, reporting zero respiratory-related mortality in approximately 29,000-bird commercial poultry field trials in India.
-
Prophylactic Benefits Against H5N1
A government-conducted challenge study demonstrated prophylactic benefits against H5N1 avian influenza, with mortality reduced by up to 60% in pre-treated groups and significantly extended time to death.
-
Strategic Development and IP Protection
MGX-0024 is a patented, GRAS-classified formulation. The company is scaling production, refining logistics, and engaging in regulatory discussions in key international markets, with commercial rollout anticipated in coming periods.
Analysis · MGRX · Industrial Applications And Services
This filing reports highly positive data for Mangoceuticals' antiviral compound MGX-0024, a significant development for a micro-cap company. The demonstrated efficacy in large-scale commercial poultry trials, achieving zero respiratory-related mortality, and the prophylactic benefits against the highly pathogenic H5N1 avian influenza strain in a controlled study, suggest a substantial market opportunity. This news could provide a much-needed positive catalyst, especially given the company's recent Nasdaq deficiency notice and ongoing S-1 filings for potential share resale. While the H5N1 lab study is small-scale and preliminary, the field trial results are robust and indicate a promising non-vaccine, non-antibiotic solution for a critical global issue in poultry health and biosecurity. Investors should monitor further regulatory progress and commercialization efforts.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.49 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $0.34 to $5.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.